Ocugen Inc (OCGN)

$1.07 -0.04 (-3.60%)
Market Cap 332.92M
Revenue (ttm) 4.06M
Net Income (ttm) -54.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,331.28%
Debt to Equity Ratio 1.74
Volume 3,493,900
Avg Vol 6,246,838
Day's Range N/A - N/A
Shares Out 292.03M
Stochastic %K 72%
Beta 4.18
Analysts Strong Sell
Price Target $6.50

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 328 4701
Address:
11 Great Valley Parkway, Malvern, United States
ZALEZPHOTO
ZALEZPHOTO Jul. 15 at 11:20 PM
$OCGN 🚨🚨🚨 HOLY NEWS FLASH 🚨🚨🚨 I just saw this and had to share here. Even though it's too early to speculate, it's impossible to not wonder if this could turn out to be a monumental gain for Ocugen, and the biggest ever of pharmaceutical case of poetic justice... Ocugen is specifically working on treatments targeting corneal endothelial cell density (ECD). A Potential Relevance Ocugen’s modifier gene therapy platform, which involves delivering genes to modulate cellular function, could hypothetically be adapted for CORNEAL ENDOTHELIAL repair, as gene therapy is an emerging strategy for corneal diseases. https://x.com/P_McCulloughMD/status/1945244894106411165
1 · Reply
luca75
luca75 Jul. 15 at 10:52 PM
$OCGN what is the current short lending rate for our shares? How can I find this information?
1 · Reply
GuppyL
GuppyL Jul. 15 at 10:42 PM
$OCGN I'm bullish but just want to point out over $1 for 10 days doesn't mean compliance.... We did that a month ago. It means that it will be taken into consideration of not being delisted. And at this point there is no threat until Dec 30th. Just hold and buy.
2 · Reply
SiejeUGA
SiejeUGA Jul. 15 at 10:25 PM
$OCGN
0 · Reply
Superior_IQ
Superior_IQ Jul. 15 at 10:08 PM
$OCGN Day 6 of 100 in minimum $1 bid compliance for the NASDAQ pricks and bears
0 · Reply
Lauragronbach
Lauragronbach Jul. 15 at 9:42 PM
$OCGN Day #6
0 · Reply
VinceJ13
VinceJ13 Jul. 15 at 9:29 PM
$OCGN 3 more days for compliance ?
1 · Reply
CaptSparow
CaptSparow Jul. 15 at 9:01 PM
$OCGN @ocubaby What "bullshit"? I mentioned the premarket was basically very weak. There is no "bullshit" about that. In the meantime @TheUrbanFarmer / @TheUrbanFarmerr was posting you need to buy or loose out. I'm not bullish or bearish on the stock, just being real. So? Who is "bullshit, and who is real?
1 · Reply
Ostocks339
Ostocks339 Jul. 15 at 8:47 PM
$OCGN adding tomorrow doing my part
1 · Reply
Mr_Charlie
Mr_Charlie Jul. 15 at 8:04 PM
$OCGN I am hopping for a positive day tomorrow. We can't have negative inflaction data delivered every day! But we can have an idiot scaring the market with tariffs!! We never know what we will get tomorrow.
1 · Reply
Latest News on OCGN
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 23, 2025, 7:30 AM EDT - 22 days ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Ocugen: Three Potential Gene-Therapy Filings By 2028

Jun 18, 2025, 4:00 PM EDT - 27 days ago

Ocugen: Three Potential Gene-Therapy Filings By 2028

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 16, 2025, 7:02 AM EDT - 4 weeks ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

Jun 11, 2025, 7:30 AM EDT - 4 weeks ago

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Jun 5, 2025, 7:02 AM EDT - 5 weeks ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025, 7:02 AM EDT - 7 weeks ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 10:02 AM EDT - 2 months ago

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025, 8:01 AM EDT - 2 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 2 months ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 29, 2025, 7:30 AM EDT - 2 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Apr 8, 2025, 8:02 AM EDT - 3 months ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 4 months ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 10:59 AM EST - 4 months ago

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 4 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 27, 2025, 8:46 AM EST - 4 months ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 8:00 AM EST - 5 months ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 12, 2025, 7:42 AM EST - 5 months ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Feb 3, 2025, 6:30 AM EST - 5 months ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 27, 2025, 6:30 AM EST - 6 months ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Jan 16, 2025, 7:30 AM EST - 6 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Jan 13, 2025, 6:30 AM EST - 6 months ago

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Dec 19, 2024, 6:38 AM EST - 7 months ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 11, 2024, 7:02 AM EST - 7 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Nov 27, 2024, 7:09 AM EST - 8 months ago

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Nov 20, 2024, 7:30 AM EST - 8 months ago

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Nov 19, 2024, 7:02 AM EST - 8 months ago

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 10:18 AM EST - 8 months ago

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Nov 8, 2024, 6:45 AM EST - 8 months ago

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Ocugen Secures $30 Million in Debt Funding

Nov 7, 2024, 6:30 AM EST - 8 months ago

Ocugen Secures $30 Million in Debt Funding

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Oct 28, 2024, 6:30 AM EDT - 9 months ago

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Oct 22, 2024, 7:02 AM EDT - 9 months ago

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Oct 17, 2024, 7:30 AM EDT - 9 months ago

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Oct 9, 2024, 6:30 AM EDT - 9 months ago

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Oct 2, 2024, 6:30 AM EDT - 10 months ago

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference

Sep 24, 2024, 7:30 AM EDT - 10 months ago

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Sep 17, 2024, 8:00 AM EDT - 10 months ago

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Sep 17, 2024, 2:25 AM EDT - 10 months ago

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Sep 9, 2024, 6:30 AM EDT - 11 months ago

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Sep 5, 2024, 7:00 AM EDT - 11 months ago

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:30 AM EDT - 11 months ago

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Aug 28, 2024, 6:30 AM EDT - 11 months ago

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Aug 26, 2024, 7:02 AM EDT - 11 months ago

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Aug 20, 2024, 9:00 AM EDT - 11 months ago

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Aug 8, 2024, 6:45 AM EDT - 1 year ago

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

Aug 5, 2024, 6:30 AM EDT - 1 year ago

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

Aug 2, 2024, 3:22 PM EDT - 1 year ago

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

Jul 31, 2024, 9:15 PM EDT - 1 year ago

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

Jul 31, 2024, 4:15 PM EDT - 1 year ago

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

Jul 29, 2024, 7:02 AM EDT - 1 year ago

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

Jul 25, 2024, 6:30 AM EDT - 1 year ago

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

ZALEZPHOTO
ZALEZPHOTO Jul. 15 at 11:20 PM
$OCGN 🚨🚨🚨 HOLY NEWS FLASH 🚨🚨🚨 I just saw this and had to share here. Even though it's too early to speculate, it's impossible to not wonder if this could turn out to be a monumental gain for Ocugen, and the biggest ever of pharmaceutical case of poetic justice... Ocugen is specifically working on treatments targeting corneal endothelial cell density (ECD). A Potential Relevance Ocugen’s modifier gene therapy platform, which involves delivering genes to modulate cellular function, could hypothetically be adapted for CORNEAL ENDOTHELIAL repair, as gene therapy is an emerging strategy for corneal diseases. https://x.com/P_McCulloughMD/status/1945244894106411165
1 · Reply
luca75
luca75 Jul. 15 at 10:52 PM
$OCGN what is the current short lending rate for our shares? How can I find this information?
1 · Reply
GuppyL
GuppyL Jul. 15 at 10:42 PM
$OCGN I'm bullish but just want to point out over $1 for 10 days doesn't mean compliance.... We did that a month ago. It means that it will be taken into consideration of not being delisted. And at this point there is no threat until Dec 30th. Just hold and buy.
2 · Reply
SiejeUGA
SiejeUGA Jul. 15 at 10:25 PM
$OCGN
0 · Reply
Superior_IQ
Superior_IQ Jul. 15 at 10:08 PM
$OCGN Day 6 of 100 in minimum $1 bid compliance for the NASDAQ pricks and bears
0 · Reply
Lauragronbach
Lauragronbach Jul. 15 at 9:42 PM
$OCGN Day #6
0 · Reply
VinceJ13
VinceJ13 Jul. 15 at 9:29 PM
$OCGN 3 more days for compliance ?
1 · Reply
CaptSparow
CaptSparow Jul. 15 at 9:01 PM
$OCGN @ocubaby What "bullshit"? I mentioned the premarket was basically very weak. There is no "bullshit" about that. In the meantime @TheUrbanFarmer / @TheUrbanFarmerr was posting you need to buy or loose out. I'm not bullish or bearish on the stock, just being real. So? Who is "bullshit, and who is real?
1 · Reply
Ostocks339
Ostocks339 Jul. 15 at 8:47 PM
$OCGN adding tomorrow doing my part
1 · Reply
Mr_Charlie
Mr_Charlie Jul. 15 at 8:04 PM
$OCGN I am hopping for a positive day tomorrow. We can't have negative inflaction data delivered every day! But we can have an idiot scaring the market with tariffs!! We never know what we will get tomorrow.
1 · Reply
Pit1908
Pit1908 Jul. 15 at 8:00 PM
$OCGN 💲🔜👀 Hold the stock price above $1.00 for ten consecutive days: 07/08 1 day $1.05✔️ +8.25% 07/09 2 days $1.13✔️ +7.62% 07/10 3 days $1.15✔️ +1.77% 07/11 4 days $1.14✔️ -0.87% 07/14 5 days $1.11✔️ -2.63% 07/15 6 days $1.07✔️ -3.60%
0 · Reply
Tilbury100
Tilbury100 Jul. 15 at 7:56 PM
$OCGN
0 · Reply
nick2341
nick2341 Jul. 15 at 7:47 PM
$OCGN ?????
0 · Reply
CaMeL036
CaMeL036 Jul. 15 at 7:46 PM
$OCGN spending nice annual leave on Corfu island and thinking about OCGN
0 · Reply
Iwantpaid
Iwantpaid Jul. 15 at 7:38 PM
$OCGN now for your viewing pleasure, i give you Shanker‘s Shitshow
1 · Reply
Honesttrader99
Honesttrader99 Jul. 15 at 7:35 PM
$OCGN lets go bulls
0 · Reply
chefETank
chefETank Jul. 15 at 7:07 PM
$OCGN no volume we need some news.
0 · Reply
Honesttrader99
Honesttrader99 Jul. 15 at 7:01 PM
$OCGN Sparow are you pulling your shit again
1 · Reply
Honesttrader99
Honesttrader99 Jul. 15 at 7:00 PM
$OCGN lets go bulls push time close her at 1.18
0 · Reply
ocubaby
ocubaby Jul. 15 at 6:48 PM
$OCGN listen everybody know what the captain wannabe sparrow guy is doing. First he begun with the bullshit lawsuits and shitting on the stock until he could get in at a low price. Then all of a sudden he became bullish, and sold out when he made profit. Now he is doing the same old shitting on this stock and hoping it will get lower so he can get in again. If you really out then why waste your time arguing with other about this stock? Dont fall for his bullshit. do your on DD and never listen to anyone.
2 · Reply
HarryA123
HarryA123 Jul. 15 at 6:47 PM
$OCGN Mutha_£
0 · Reply
BioBuddha
BioBuddha Jul. 15 at 6:38 PM
$OCGN wow ! This is still around. Isn’t this the same fraudulent company that touted their deal with India in selling covaxin ( the India made covid vaccine) and didn’t sell squat ???? How dumb one must be to continue to buy this stock
0 · Reply